Open AccessSingle High‐dose Vitamin D3 Supplementation in Pediatric Patients With Inflammatory Bowel Disease and Hypovitaminosis D
Author(s) -
Lee Rose,
Maltz Ross M.,
Crandall Wallace V.,
Plogsted Steven W.,
Shaikhkhalil Ala K.,
Bowden Sasigarn A.,
Mezoff Ethan A.
Publication year - 2020
Publication title -
journal of pediatric gastroenterology and nutrition
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 1.206
H-Index - 131
eISSN - 1536-4801
pISSN - 0277-2116
DOI - 10.1097/mpg.0000000000002590
Subject(s) - medicine , vitamin d and neurology , gastroenterology , regimen , vitamin d deficiency , inflammatory bowel disease , clinical endpoint , hypovitaminosis , vitamin , randomized controlled trial , surgery , disease
Objectives: The primary aim was to determine the effectiveness of a single high‐dose of oral vitamin D3 (stoss therapy) in children with inflammatory bowel disease (IBD) and hypovitaminosis D. Our secondary aim was to examine the safety of stoss therapy. Methods: We conducted a randomized, prospective study of 44 patients, ages 6 to 21 years, with IBD and 25‐hydroxyvitamin D (25‐OHD) concentrations <30 ng/mL. Patients were randomized to receive 50,000 IU of vitamin D3 once weekly for 6 weeks (standard of care, SOC group) or 300,000 IU once (stoss group). Serum 25‐OHD levels were obtained at baseline, 4 and 12 weeks. Safety monitoring labs were performed at week 4. Results: Thirty‐nine of 44 enrolled patients (19 stoss, 20 SOC) completed the study. Baseline vitamin D levels were not significantly different between the groups. Stoss therapy resulted in a substantial rise in 25‐OHD levels at week 4, equivalent to the weekly regimen (53.6 ± 17.3 vs 54.6 ± 17.5 ng/mL). At week 12, serum 25‐OHD levels decreased in both groups, significantly lower in the stoss group, but remained close to 30 ng/mL (29.8 ± 7.1 vs 40.4 ± 11.9 ng/mL, P = 0.04). A significant interaction with treatment group over time was observed ( P = 0.0003). At the week‐4 time point, all patients who received stoss therapy had normal serum calcium and PTH levels. Eighty percentage of patients preferred stoss therapy to the weekly regimen. Conclusions: Stoss therapy was safe and effective in raising 25‐OHD in children with IBD commensurate to that of the weekly regimen.